12:00 AM
 | 
Nov 13, 2014
 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information
Endocrine/metabolic disease
Diabetes; obesity Ceramide synthase 6 (CERS6; LASS6) In vitro and mouse studies suggest...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >